Potential urinary biomarkers of nephrotoxicity in cyclophosphamide-treated rats investigated by NMR-based metabolic profiling
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Sa Rang | - |
dc.contributor.author | Hyun, Sun-Hee | - |
dc.contributor.author | Lee, Seul Gi | - |
dc.contributor.author | Kim, Jin-Young | - |
dc.contributor.author | Kim, So-Hyun | - |
dc.contributor.author | Park, Sang-Jin | - |
dc.contributor.author | Moon, Kyoung-Sik | - |
dc.contributor.author | Sul, Donggeun | - |
dc.contributor.author | Kim, Dong Hyun | - |
dc.contributor.author | Choi, Hyung-Kyoon | - |
dc.date.available | 2019-03-08T09:36:34Z | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 1095-6670 | - |
dc.identifier.issn | 1099-0461 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/4739 | - |
dc.description.abstract | The anticancer-drug cyclophosphamide (CP) is known to have nephrotoxicity. The aim of this study was to identify urinary biomarkers indicating CP-induced nephrotoxicity. We investigated the urine metabolic profiles using nuclear magnetic resonance spectrometry of rats administered with single high-doses of CP (0, 30, and 100 mg/kg body weight) and daily low-doses over a 4-week period (0, 1, 3, and 10 mg/kg body weight). Among 18 identified urinary metabolites, 2-oxoglutarate, citrate, hippurate, formate, valine, and alanine for short-term and 2-oxoglutarate, citrate, hippurate, isoleucine, leucine, allantoin, valine, and lysine for long-term were selected as potential biomarkers. Pathway-enrichment analysis suggested that the urinary metabolism of CP is related to valine, leucine, and isoleucine biosynthesis; taurine and hypotaurine metabolism; glyoxylate and dicarboxylate metabolism; citrate cycle; and alanine, aspartate, and glutamate metabolism, with high pathway impact. The potential biomarkers obtained in this study could be used to monitor CP-induced nephrotoxicity relative to dose and treatment time. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Potential urinary biomarkers of nephrotoxicity in cyclophosphamide-treated rats investigated by NMR-based metabolic profiling | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/jbt.21871 | - |
dc.identifier.bibliographicCitation | JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, v.31, no.3 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000397303300007 | - |
dc.identifier.scopusid | 2-s2.0-85005952243 | - |
dc.citation.number | 3 | - |
dc.citation.title | JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY | - |
dc.citation.volume | 31 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Cyclophosphamide | - |
dc.subject.keywordAuthor | H-1-NMR | - |
dc.subject.keywordAuthor | Metabolic profiling | - |
dc.subject.keywordAuthor | Nephrotoxicity | - |
dc.subject.keywordAuthor | Urine | - |
dc.subject.keywordPlus | TOF-MS | - |
dc.subject.keywordPlus | METABONOMICS | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordPlus | SPECTROSCOPY | - |
dc.subject.keywordPlus | SERUM | - |
dc.subject.keywordPlus | IFOSFAMIDE | - |
dc.subject.keywordPlus | CREATININE | - |
dc.subject.keywordPlus | DISCOVERY | - |
dc.subject.keywordPlus | PLASMA | - |
dc.subject.keywordPlus | DAMAGE | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Toxicology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Toxicology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.